Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Inoteb

Lfb Biotechnologies

Foundation Nationale De Transfusion Sanguine

Lfb Sa

Biocoral Inc.

Labratoire Francais Du Fractionnement Et Des Biotechnologies

Laboratoire Fancais Du Fractionnement Et Des Biotechnologies

Laboratoiore Francais Du Fractionnement Et Des Biotechnologies

Roland Schmitthaeusler

Sami Chtourou

Annie Bardat

Abdessatar Chtourou

Jean-Louis Patat

Olivier Marcel Delmas

Edith Begin

Bruno Padrazzi

Nassirah Khandoudi

Olivier Just

Stephane Boyer

Paul Boulange

Michel Nogre

Alain Largeteau

Jean-Christophe Fricain

Yann Lepetitcorps

Philippe Paolantonacci

Jacky Lirochon

Francoise Bridey

Vincent Souillac

Abdessatar Sami Chtourou

The invention relates to an albumin-purification method comprising a step consisting in subjecting an aqueous albumin solution, with a concentration of between 15 g/l and 80 g/l and a pH of not less than 7, to nanofiltration in a temperature range of between 15 DEG C. and 55 DEG C. The invention also relates to: a virally-safe aqueous albumin solution which can be obtained using the inventive method and in which the sites for the transport and binding of the active therapeutic ingredients of the albumin are available; and an albumin composition for therapeutic use, which is obtained by adapting the albumin solution that is intended for clinical use.

Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing the same

The invention relates to an albumin-purification method comprising a step consisting in subjecting an aqueous albumin solution, with a concentration of between 15 g/l and 80 g/l and a pH of not lass than 7, to nanofiltration in a temperature range of between 15 DEG C and 55 DEG C. The invention also relates to: a virally-safe aqueous albumin solution which can be obtained using the inventive method and in which the sites for the transport and binding of the active therapeutic ingredients of the albumin are available; and an albumin composition for therapeutic use, which is obtained by adapting the albumin solution that is intended for clinical use.

This invention is related to a stabilizing formulation for immunoglobulins G compositions comprising a sugar alcohol, glycine and a non-ionic detergent, which is suitable for the stabilization of immunoglobulins G compositions in liquid form and in lyophilized form. The invention also relates to an immunoglobulins G composition in liquid form or in lyophilized form comprising said stabilizing formulation.

Method for stabilising an immunoglobulin G composition in liquid form

Stabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form

An ion-exchange chromatography support for reducing the ADAMTS13 amount present in a plasma-derived solution containing human von Willebrand factor. The support includes a large-pore, vinyl polymer-type resin bearing DEAE groups, and a buffer including trisodium citrate, sodium chloride, calcium chloride, glycine and lysine.

Use of a chromatography substrate for reducing the amount of ADAMTS13 in a solution derived from plasma

La present invention pertains to a composition of plasma-derived virally-safe factor VIII, obtained after nanometric filtration, said composition comprising von Willebrand factor (vWF) at a rate of 15% or less of decamers and higher multimers. Such compositions have a reduction factor of the virus titre higher than 4 log and are thus suitable for treatment of hemophilia.

Virally-safe factor VIII with a low content of higher multimers

The invention concerns a new medicinal product for the treatment of arboviruses, i.e.. a concentrate of immunoglobulins and F(ab)'2 and/or Fab fragments specific to said arbovirus as well as its process of preparation.

Medicinal concentrate of arbovirus specific immunoglobulins and F(ab)'2 and/or Fab fragments

The present invention provides a method of extracting organic substances present in coral, which consists in treating the coral with a fluid or a mixture of fluids in the supercritical state without modifying the crystalline structure of said coral, at a temperature of less than 270&#xb0; C. and at a pressure which is much higher than the critical pressure of said fluid or mixture of fluids, for example of the order of at least 3 times, and preferably at least 5 times said critical pressure. It also provides coral obtained by said method and bone substitutes fabricated from said coral.

Coral purification method and coral thus obtained

The invention concerns a method for preparing human immunoglobulin concentrates for therapeutic use, from plasma or a plasma fraction. The method comprises pre-purification and a single anion-exchange chromatography carried out at alkaline pH, thereby enabling the immunoglobulins to be retained on the chromatographic support and fractionated. The method enables to obtain IgG, IgA and IgM concentrates.

Method for preparing human immunoglobulin concentrates for therapeutic use

By placing a blood plasma in contact with a blood coagulation contact phase activator, before or during preparation of a fibrinogen-based biological glue, a preactivated biological glue is obtained which does not coagulate spontaneously but which is capable of coagulating in less than 5 minutes simply by the addition of calcium ions, without the addition of thrombin. The process has application to the field of surgery.

Method of preparing a biological glue able to coagulate simply by

A method is described for decontaminating or sterilizing a vacuum sealed container, particularly after a lyophilization cycle, wherein one or a plurality of containers containing microorganisms or dangerous products by introducing an aqueous gas or liquid into the container after dehydration. Also described is a device for performing the method.

Method for decontaminating or sterilizing 'in situ' a vacuum sealed

Method of preparing a biological adhesive enriched with platelet

Growing community of inventors

Montigny le Bretonneux, France

Roland Schmitthaeusler